Modern Retina Summer 2022

This affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching and reference purposes.

The investigators retrospectively analyzed treatment-naive eyes with DME which received intravitreal treatment with either ranibizumab 0.5 mg or aflibercept 2 mg. All data were collected in the Fight Retinal Blindness! registry.

CAM encourages corneal healing in patients with ocular surface disease.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal drug delivery.

A window into the world of academic retina practice today.

Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.